The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

16 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
44
Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2.EBI
University of Texas Southwestern Medical Center
22
Development of inhibitors of the PAS-B domain of the HIF-2a transcription factor.EBI
University of Texas Southwestern Medical Center
12
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.EBI
National Cancer Institute-Frederick
6
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2a induced gene expression.EBI
Nci-Frederick
18
Proline Analogues in Drug Design: Current Trends and Future Prospects.EBI
Enamine Ltd.
13
Recent progress in the development of hypoxia-inducible factor 2α (HIF-2α) modulators: Inhibitors, agonists, and degraders (2009-2024).EBI
Hubei Polytechnic University
8
Identification of 3-aryl-5-methyl-isoxazole-4-carboxamide derivatives and analogs as novel HIF-2α agonists through docking-based virtual screening and structural modification.EBI
Zhejiang University
41
Discovery of Cycloalkyl[EBI
Merck Healthcare
11
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α (HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia.EBI
China Pharmaceutical University
6
Inhibitors of Hypoxia-Inducible Factors as Treatment for Cancer.EBI
Therachem Research Medilab
10
3-[(1EBI
Peloton Therapeutics
18
Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications.EBI
Shengjing Hospital of China Medical University
54
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385).EBI
Peloton Therapeutics
15
PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENTBDB
Hana Pharm
29
Cyanopyrrolidine derivatives as inhibitors for DUBsBDB
Mission Therapeutics